Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis and Drugs for Neglected Diseases initiative (DNDi) have entered into a three-year research collaboration to generate new drugs for nine neglected tropical diseases (NTDs).
Subscribe to our email newsletter
The agreement covers kinetoplastid diseases (leishmaniases, Chagas disease, and human African trypanosomiasis), helminth infections (lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis), and dracunculiasis, fascioliasis, and schistosomiasis diseases.
Under the agreement, Sanofi is expected to initially bring molecules from its libraries into the partnership, whereas both the parties will collaborate in research activities on molecular scaffolds.
The core of the agreement lies in the management of intellectual property generated through the collaboration.
The rights to results produced by this partnership will be coowned by Sanofi and DNDi.
DNDi executive director Bernard Pecoul said they believe that this level of private-sector involvement in open-research collaboration to deliver appropriate medicines as public goods is vital to addressing the needs of the most vulnerable populations of the world.
"The agreement allows DNDi to continue making science work more efficiently for the patients who need it most," Pecoul said.